Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing